{"success":true,"data":{"pressRelease":{"id":"167213","rtpr_id":"nBw211GvRa-20261013","ticker":"ENTA","exchange":"NASDAQ","all_tickers":["ENTA"],"title":"Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026","author":"Business Wire","published_at":"2026-10-13T11:00:00.142Z","article_body":"Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily,\nN-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial\nVirus, at IDWeek™ 2026\n\nEnanta Pharmaceuticals, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.enanta.com%2F&esheet=54618778&newsitemid=20261013575271&lan=en-US&anchor=Enanta+Pharmaceuticals%2C+Inc.&index=1&md5=86cf5f996ea0b13f118dcc3000f1ac18)\n(NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating\nnovel, small molecule drugs for viral infections and immunological diseases,\ntoday announced that data for zelicapavir, its oral, once-daily, N-protein\ninhibitor in development for the treatment of respiratory syncytial virus\n(RSV), will be presented at IDWeek™ 2026 being held October 21-24, 2026\nvirtually and at the Walter E. Washington Convention Center in Washington, DC.\n\nDetails of the presentation are as follows:\n\nPoster Title: Zelicapavir Decreases Time to Complete RSV Symptom Resolution,\nHospitalization and Viral Load in a Global, Randomized, Double-Blinded,\nPlacebo (PBO)-Controlled Phase 2 Trial of High-Risk Adults\n\nPoster Session: Novel Agents\n\nPoster Number: 3\n\nDate: Thursday October 22, 2026\n\nTime: 12:15 PM - 1:30 PM ET\n\nLocation: Poster Hall B-C\n\nPresenter: Christopher E. Harris, M.D.\n\nThe poster will be available to view on the conference platform during the\nconference and on the Company’s website here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enanta.com%2Fscience%2F%23publications&esheet=54618778&newsitemid=20261013575271&lan=en-US&anchor=here&index=2&md5=98a73ce91e8104088790b2568c58fdba)\n. Further information about IDWeek™ 2026 can be found here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fidweek.org&esheet=54618778&newsitemid=20261013575271&lan=en-US&anchor=here&index=3&md5=9443dc7844518409ee29847794f9f36d)\n.\n\nAbout Enanta Pharmaceuticals, Inc.\n\nEnanta is using its robust, chemistry-driven approach and drug discovery\ncapabilities to become a leader in the discovery and development of small\nmolecule drugs for viral infections and immunological diseases. In virology,\nEnanta’s clinical programs are focused on the development of\nfirst-in-disease and best-in-disease treatments for respiratory syncytial\nvirus (RSV). The Company’s immunology pipeline aims to develop treatments\nfor inflammatory diseases by targeting key drivers of the type 2 immune\nresponse, with KIT, STAT6 and MRGPRX2 inhibition.\n\nGlecaprevir, a protease inhibitor discovered by Enanta, is part of the only\ntreatment approved for curing both acute and chronic hepatitis C virus (HCV)\ninfection and is sold by AbbVie in numerous countries under the tradenames\nMAVYRET(®) (U.S.) and MAVIRET(®) (ex-U.S.) (glecaprevir/pibrentasvir). A\nportion of Enanta’s royalties from HCV products developed under its\ncollaboration with AbbVie contribute ongoing funding to Enanta’s operations.\nPlease visit www.enanta.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.enanta.com&esheet=54618778&newsitemid=20261013575271&lan=en-US&anchor=www.enanta.com&index=4&md5=6b0f8701d6561d30a3b34c38b91c4a76)\nfor more information.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261013575271/en/\n(https://www.businesswire.com/news/home/20261013575271/en/)\n\nMedia and Investors Contact \n\nJennifer Viera\n\n617-744-3848\n\njviera@enanta.com (mailto:jviera@enanta.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw211GvRa-20261013","title":"Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026","author":"Business Wire","ticker":"ENTA","created":"2026-10-13T11:00:00.142Z","tickers":["ENTA"],"exchange":"NASDAQ","article_body":"Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily,\nN-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial\nVirus, at IDWeek™ 2026\n\nEnanta Pharmaceuticals, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.enanta.com%2F&esheet=54618778&newsitemid=20261013575271&lan=en-US&anchor=Enanta+Pharmaceuticals%2C+Inc.&index=1&md5=86cf5f996ea0b13f118dcc3000f1ac18)\n(NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating\nnovel, small molecule drugs for viral infections and immunological diseases,\ntoday announced that data for zelicapavir, its oral, once-daily, N-protein\ninhibitor in development for the treatment of respiratory syncytial virus\n(RSV), will be presented at IDWeek™ 2026 being held October 21-24, 2026\nvirtually and at the Walter E. Washington Convention Center in Washington, DC.\n\nDetails of the presentation are as follows:\n\nPoster Title: Zelicapavir Decreases Time to Complete RSV Symptom Resolution,\nHospitalization and Viral Load in a Global, Randomized, Double-Blinded,\nPlacebo (PBO)-Controlled Phase 2 Trial of High-Risk Adults\n\nPoster Session: Novel Agents\n\nPoster Number: 3\n\nDate: Thursday October 22, 2026\n\nTime: 12:15 PM - 1:30 PM ET\n\nLocation: Poster Hall B-C\n\nPresenter: Christopher E. Harris, M.D.\n\nThe poster will be available to view on the conference platform during the\nconference and on the Company’s website here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.enanta.com%2Fscience%2F%23publications&esheet=54618778&newsitemid=20261013575271&lan=en-US&anchor=here&index=2&md5=98a73ce91e8104088790b2568c58fdba)\n. Further information about IDWeek™ 2026 can be found here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fidweek.org&esheet=54618778&newsitemid=20261013575271&lan=en-US&anchor=here&index=3&md5=9443dc7844518409ee29847794f9f36d)\n.\n\nAbout Enanta Pharmaceuticals, Inc.\n\nEnanta is using its robust, chemistry-driven approach and drug discovery\ncapabilities to become a leader in the discovery and development of small\nmolecule drugs for viral infections and immunological diseases. In virology,\nEnanta’s clinical programs are focused on the development of\nfirst-in-disease and best-in-disease treatments for respiratory syncytial\nvirus (RSV). The Company’s immunology pipeline aims to develop treatments\nfor inflammatory diseases by targeting key drivers of the type 2 immune\nresponse, with KIT, STAT6 and MRGPRX2 inhibition.\n\nGlecaprevir, a protease inhibitor discovered by Enanta, is part of the only\ntreatment approved for curing both acute and chronic hepatitis C virus (HCV)\ninfection and is sold by AbbVie in numerous countries under the tradenames\nMAVYRET(®) (U.S.) and MAVIRET(®) (ex-U.S.) (glecaprevir/pibrentasvir). A\nportion of Enanta’s royalties from HCV products developed under its\ncollaboration with AbbVie contribute ongoing funding to Enanta’s operations.\nPlease visit www.enanta.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.enanta.com&esheet=54618778&newsitemid=20261013575271&lan=en-US&anchor=www.enanta.com&index=4&md5=6b0f8701d6561d30a3b34c38b91c4a76)\nfor more information.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261013575271/en/\n(https://www.businesswire.com/news/home/20261013575271/en/)\n\nMedia and Investors Contact \n\nJennifer Viera\n\n617-744-3848\n\njviera@enanta.com (mailto:jviera@enanta.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-13T11:00:00.206250236Z","server_sent_at_ms":1791889200206},"received_at":"2026-10-13T11:00:00.257Z","source_url":"https://www.businesswire.com/news/home/20261013575271/en/"},"analysis":{"id":"155535","press_release_id":"167213","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Enanta Pharmaceuticals will present Phase 2 data for zelicapavir, its oral once-daily N-protein inhibitor for RSV, at IDWeek 2026 on October 22 in Washington, DC.\n\nThe poster covers a global, randomized, placebo-controlled Phase 2 trial in high-risk adults, reporting decreases in time to symptom resolution, hospitalization, and viral load.\n\nThe data preview is a visibility event rather than a results release; the actual trial figures land at the conference, where investors will assess the RSV program's path forward.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Conference data teaser for ENTA's lead RSV asset -- watch the October 22 poster for actual Phase 2 results."},"keyFigures":{"drugName":"zelicapavir","phaseOfTrial":"Phase 2"},"quotedText":"Zelicapavir Decreases Time to Complete RSV Symptom Resolution, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo (PBO)-Controlled Phase 2 Trial of High-Risk Adults","namedEntities":{"people":[{"name":"Christopher E. Harris, M.D.","role":"poster presenter"},{"name":"Jennifer Viera","role":"Media and Investors Contact"}],"products":["zelicapavir","MAVYRET","MAVIRET","glecaprevir/pibrentasvir"],"companies":[{"name":"Enanta Pharmaceuticals, Inc.","ticker":"ENTA"},{"name":"AbbVie","relationship":"partner (HCV collaboration / MAVYRET-MAVIRET marketer)"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Announcement of an upcoming poster presentation of Phase 2 zelicapavir data at IDWeek 2026; no new data disclosed yet. Modest positive visibility for the RSV pipeline, but the actual results are not in this release."},"tickerRelevance":{"others":[],"primary":"ENTA"},"globalImportance":20,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"conference presentation announcement, no new data","eventGravityNote":"Phase 2 data drop could be more material on Oct 22"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Enanta Pharmaceuticals will present Phase 2 data for zelicapavir, its oral once-daily N-protein inhibitor for RSV, at IDWeek 2026 on October 22 in Washington, DC.\n\nThe poster covers a global, randomized, placebo-controlled Phase 2 trial in high-risk adults, reporting decreases in time to symptom resolution, hospitalization, and viral load.\n\nThe data preview is a visibility event rather than a results release; the actual trial figures land at the conference, where investors will assess the RSV program's path forward.","key_figures":{"drugName":"zelicapavir","phaseOfTrial":"Phase 2"},"named_entities":{"people":[{"name":"Christopher E. Harris, M.D.","role":"poster presenter"},{"name":"Jennifer Viera","role":"Media and Investors Contact"}],"products":["zelicapavir","MAVYRET","MAVIRET","glecaprevir/pibrentasvir"],"companies":[{"name":"Enanta Pharmaceuticals, Inc.","ticker":"ENTA"},{"name":"AbbVie","relationship":"partner (HCV collaboration / MAVYRET-MAVIRET marketer)"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T11:00:05.424Z","global_importance":20,"audience_relevance":20,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"conference presentation announcement, no new data","eventGravityNote":"Phase 2 data drop could be more material on Oct 22"}},"durationMs":5051,"modelName":"glm-5.3-flashx"}}